Skip to Content

Stock picker: Lincare looks good

Stock picker: Lincare looks good

CLEARWATER, Fla. - While potential cuts to Medicare Part B raise red flags for some stock analysts following Lincare, that's not the case for stock picker Rich Moroney. According to Moroney: "Probably the biggest risk facing Lincare is the company's exposure to Medicare-reimbursed respiratory medications, which comprise about 20% of sales. Some reduction is expected in the reimbursement rates that Medicare provides for Part B, drugs. While Lincare's management does not expect Congress to act this year, it concedes that a 20% reduction in Part B drug pricing could lower 2003 per-share earnings by $0.17 to $0.20. Such an outcome would be a clear negative for the stock. But it would be one time in nature, and Congress could partly offset such a cut with an increase in the reimbursement for the service component of respiratory care." HME

Comments

To comment on this post, please log in to your account or set up an account now.